Search
Regdanvimab
go.drugbank.com/drugs/DB16405ApprovedWithdrawnTrials investigating the use of regdanvimab as a therapeutic candidate for the treatment of COVID-19 began in mid-2020. … [A235830,A241995] It received its first full approval in South Korea in September 2021,[A241995] followed by the EU in November 2021.[L39130]
Profenamine
go.drugbank.com/drugs/DB00392ApprovedProfenamine (also known as ethopropazine) is a medication derived from phenothiazine. It is primarily used as an antidyskinetic to treat Parkinsonism. … It is sold under the trade name Parsitan in Canada.[L46812] In the US, the marketing of profenamine has been discontinued.[L46817]
Synonyms: N,N-diethyl-1-(10H-phenothiazin-10-yl)-2-propanamine, N,N-diethyl-α-methyl-10H-phenothiazine-10-ethanamineNandrolone decanoate
go.drugbank.com/drugs/DB08804ApprovedIllicitInvestigational[A233789,A233849,L32564,L9464] The process for creating esters of [nandrolone] was patented in Spain in 1959[L33244] and in 1960, it was described as having a long duration of action and strong anabolic … Nandrolone decanoate, also known as nandrolone caprinate, is an alkylated anabolic steroid indicated in the management of anemia of renal insufficiency and as an adjunct therapy in the treatment of senile
Categories: Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substratesUpadacitinib
go.drugbank.com/drugs/DB15091ApprovedInvestigationalUpadacitinib is an oral Janus kinase (JAK)1-selective inhibitor and a disease-modifying antirheumatic drug (DMARD) used in the treatment of rheumatoid arthritis to slow down disease progression. … More recently, it has also been approved for the treatment of giant cell arteritis in adults and active polyarticular juvenile idiopathic arthritis in patients aged 2 years and older.[L10896]
Recombinant Cholera Toxin B Subunit
go.drugbank.com/drugs/DB11643ApprovedInvestigationalRecombinant Cholera Toxin B Subunit is an ingredient in the EMA-authorised product Dukoral.
Categories: Compounds used in a research, industrial, or household settingPlozasiran
go.drugbank.com/drugs/DB18997ApprovedInvestigationalPlozasiran contains a covalently linked ligand containing three N-acetylgalactosamine (GalNAc) residues to facilitate delivery to hepatocytes where it works to reduce triglyceride levels. … [L45864] Plozasiran was first approved by the FDA on November 18th, 2025, to reduce triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS).[L54603]
Lusutrombopag
go.drugbank.com/drugs/DB13125ApprovedInvestigationalIn two randomized, double-blind, placebo-controlled trials, patients with chronic liver disease and severe thrombocytopenia who were undergoing an invasive procedure with a platelet count less than 50 … x 10^9/L were administered lusutrombopag orally [L4166].
Bendroflumethiazide
go.drugbank.com/drugs/DB00436ApprovedInvestigationalA thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. It has been used in the treatment of familial hyperkalemia, hypertension, edema, and urinary tract disorders. … (From Martindale, The Extra Pharmacopoeia, 30th ed, p810)
Azelastine
go.drugbank.com/drugs/DB00972ApprovedInvestigationalAzelastine, a phthalazine derivative, is an antihistamine available as an intranasal spray for the treatment of allergic and vasomotor rhinitis and as an ophthalmic solution for the treatment of allergic … [L8240,L8270] It is a racemic mixture, though there is no noted difference in pharmacologic activity between enantiomers, and was first granted FDA approval in 1996.
Mixtures: N-S-4Trimetrexate
go.drugbank.com/drugs/DB01157ApprovedA nonclassical folic acid inhibitor through its inhibition of the enzyme dihydrofolate reductase. … It is being tested for efficacy as an antineoplastic agent and as an antiparasitic agent against pneumocystis pneumonia in AIDS patients. Myelosuppression is its dose-limiting toxic effect.